Axiogenesis is happy to announce the addition of a new product to the Cor.4U product family:
A further matured version of our human iPSC-derived cardiomyocytes.
For our new MaturedCor.4U, we have used our expertise and innovative technology to optimize and extend the cardiomyocytes culturing and maturation process.
MaturedCor.4U possess more adult-like properties and represent an ideal tool for specialized applications including manual and automated patch clamp for functional analysis of ion channels in drug safety / toxicology and drug screening.
Watch out for more product news to come up in the next weeks.
Axiogenesis is now looking for beta testers to drive customer-specific characterization of the Matured Cor.4U cells.
We expect cells to be shipped in July 2016.